Analysts Offer Predictions for Sarepta Therapeutics, Inc.’s FY2024 Earnings (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Stock analysts at William Blair reduced their FY2024 earnings estimates for Sarepta Therapeutics in a research report issued on Wednesday, May 1st. William Blair analyst T. Lugo now forecasts that the biotechnology company will post earnings per share of $6.10 for the year, down from their previous forecast of $6.66. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.23 per share.

Several other research analysts have also recently weighed in on SRPT. Barclays lifted their price target on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. Wedbush reiterated an “outperform” rating and set a $224.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, February 29th. Cantor Fitzgerald restated a “neutral” rating and set a $128.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, May 2nd. Evercore ISI lifted their target price on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the company an “in-line” rating in a research note on Tuesday, February 20th. Finally, UBS Group lifted their target price on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Four equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $160.60.

Sarepta Therapeutics Trading Up 0.7 %

NASDAQ:SRPT opened at $136.04 on Monday. The company has a current ratio of 4.05, a quick ratio of 3.44 and a debt-to-equity ratio of 1.18. Sarepta Therapeutics has a 12 month low of $55.25 and a 12 month high of $159.89. The company has a market cap of $12.86 billion, a PE ratio of 1,236.73 and a beta of 0.95. The company has a 50 day simple moving average of $125.47 and a two-hundred day simple moving average of $111.07.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.84. The company had revenue of $413.50 million during the quarter, compared to the consensus estimate of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The firm’s quarterly revenue was up 63.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.44) earnings per share.

Insider Transactions at Sarepta Therapeutics

In other news, CFO Ian Michael Estepan sold 1,200 shares of the business’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $128.30, for a total transaction of $153,960.00. Following the transaction, the chief financial officer now directly owns 39,114 shares in the company, valued at $5,018,326.20. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Director Stephen Mayo sold 3,135 shares of the company’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $122.96, for a total transaction of $385,479.60. Following the transaction, the director now owns 6,621 shares of the company’s stock, valued at $814,118.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Ian Michael Estepan sold 1,200 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $128.30, for a total transaction of $153,960.00. Following the transaction, the chief financial officer now directly owns 39,114 shares in the company, valued at approximately $5,018,326.20. The disclosure for this sale can be found here. Insiders have sold a total of 25,731 shares of company stock worth $3,248,319 over the last ninety days. 7.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Sei Investments Co. lifted its stake in shares of Sarepta Therapeutics by 9.5% in the 1st quarter. Sei Investments Co. now owns 61,451 shares of the biotechnology company’s stock valued at $7,956,000 after purchasing an additional 5,332 shares in the last quarter. Swiss National Bank raised its holdings in Sarepta Therapeutics by 6.3% in the first quarter. Swiss National Bank now owns 166,183 shares of the biotechnology company’s stock valued at $21,514,000 after buying an additional 9,900 shares during the period. Oppenheimer Asset Management Inc. grew its stake in Sarepta Therapeutics by 32.0% during the first quarter. Oppenheimer Asset Management Inc. now owns 3,604 shares of the biotechnology company’s stock worth $467,000 after buying an additional 874 shares during the period. PFG Advisors purchased a new stake in Sarepta Therapeutics during the first quarter worth approximately $591,000. Finally, Howland Capital Management LLC acquired a new stake in shares of Sarepta Therapeutics in the first quarter worth $211,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.